INVESTOR ALERT: Holzer & Holzer Continues Investigation of Solid Biosciences, Inc.

ATLANTA--()--Holzer & Holzer, LLC continues to investigate whether Solid Biosciences, Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB) complied with the federal securities laws. On March 14, 2018, the Company announced that its SGT-001 clinical trial had been put on hold by the FDA. The price of Solid Biosciences stock fell significantly following the announcement.

If you purchased Solid Biosciences common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Alexandria P. Rankin, Esq. at arankin@holzerlaw.com, or call the firm by toll-free telephone at (888) 508-6832.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

Contacts

Holzer & Holzer, LLC
Corey D. Holzer, Esq., 888-508-6832
cholzer@holzerlaw.com
or
Alexandria P. Rankin, Esq., 888-508-6832
arankin@holzerlaw.com

Release Summary

Holzer investigates Solid Bioscience

Contacts

Holzer & Holzer, LLC
Corey D. Holzer, Esq., 888-508-6832
cholzer@holzerlaw.com
or
Alexandria P. Rankin, Esq., 888-508-6832
arankin@holzerlaw.com